Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Novel Therapeutics
100%
Splicing Modulation
100%
Diffuse Malignant Peritoneal Mesothelioma
100%
SF3B1
42%
SF3b
42%
Survival Rate
28%
E7107
28%
Pladienolide B
28%
Therapeutic Target
14%
RNA Sequencing (RNA-seq)
14%
High-level Expression
14%
Clinical Outcomes
14%
Poor Clinical Outcomes
14%
Therapeutic Potential
14%
Apoptosis
14%
Gene Expression Profiling
14%
Molecular Prognostic Marker
14%
Drug-induced
14%
Antitumor Activity
14%
Deregulation
14%
Alternative Splicing
14%
Cellular Pathways
14%
Orthotopic Model
14%
Multivariate Analysis
14%
Univariate Analysis
14%
Disease Progression
14%
Splicing Analysis
14%
Splicing Modulator
14%
In Vitro Activity
14%
IC50 Value
14%
Functional Assay
14%
Bioluminescent
14%
Cytotoxic Activity
14%
Primary Cell Culture
14%
In Vitro Screening
14%
Tissue Expression
14%
Tissue Microarray
14%
Mesothelioma Cells
14%
Regional Chemotherapy
14%
Splicing Alteration
14%
Antitumor Activity in Vivo
14%
RT-PCR Assay
14%
Prognostic Potential
14%
In Vivo Antitumor Activity
14%
Cancer Cell Viability
14%
Oncogenic Pathways
14%
Potential Prognostic Factors
14%
Immunohistochemical Assessment
14%
Meayamycin
14%
Immunology and Microbiology
Survival Rate
100%
Antineoplastic Activity
100%
Mouse Model
50%
Cell Viability
50%
Cancer Cell
50%
Cytotoxicity
50%
Cell Cycle
50%
RNA Sequence
50%
Reverse Transcription Polymerase Chain Reaction
50%
IC50
50%
Primary Cell Culture
50%
Gene Expression Assay
50%
Bioluminescence
50%
Medicine and Dentistry
Peritoneum Mesothelioma
100%
Survival Rate
28%
Prognostic Factor
28%
Antineoplastic Activity
28%
Cancer Cell
14%
Cell Viability
14%
In Vitro
14%
RNA Sequence
14%
Cell Culture
14%
Gene Expression Profiling
14%
Cytotoxicity
14%
Cell Cycle
14%
Multivariate Analysis
14%
Univariate Analysis
14%
Disease Exacerbation
14%
IC50
14%
Tissue Microarray
14%
Reverse Transcription Polymerase Chain Reaction
14%
In Vitro Screening
14%
Apoptosis
14%
Chemotherapy
14%
Bioluminescence
14%
Pharmacology, Toxicology and Pharmaceutical Science
Peritoneal Mesothelioma
100%
Antitumor Activity
28%
Survival Rate
28%
Malignant Neoplasm
14%
Mouse Model
14%
Chemotherapy
14%
RNA-Sequencing
14%
Disease Exacerbation
14%
Cell Culture
14%
Cell Viability
14%
IC50
14%
Apoptosis
14%
In Vitro Screening
14%
Cytotoxicity
14%